We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
AnaSpec Introduces b- Secretase Enzyme and Assay
Product News

AnaSpec Introduces b- Secretase Enzyme and Assay

AnaSpec Introduces b- Secretase Enzyme and Assay
Product News

AnaSpec Introduces b- Secretase Enzyme and Assay


Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "AnaSpec Introduces b- Secretase Enzyme and Assay"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AnaSpec has announced its latest offering of b-amyloid peptides and Alzheimer’s related research products – the human recombinant b-secretase enzyme.

b- secretase (BACE1) is a key protease involved in the production of b-amyloid peptides found in extracellular amyloid plaques of patients with Alzheimer’s disease (AD). This enzyme has been implicated as an important target for anti-amyloid therapy of AD.

The recombinant human BACE1 contains the catalytic domain and a C-terminal His tag. The protein was expressed as inclusion bodies in E. coli. It was refolded and purified using ion exchange and IMAC chromatography. Enzyme activity can be measured in fluorescence resonance energy transfer (FRET) substrate based assays. 100 ng of b-secretase is sufficient for this FRET-based assay.

AnaSpec’s SensoLyte™ 520 b-Secretase Assay Kit (cat# 71144) is the industry’s only long wavelength assay kit in the green range. This kit is a fluorimetric assay kit. It employs a FRET peptide (mentioned above), facilitating high throughput screening of b-secretase targeting drug candidates.

The sequence of this FRET peptide is derived from the b-secretase cleavage site of beta-amyloid precursor protein (APP) with Swedish mutation. This mutation enhances the susceptibility of APP to b-secretase and results in an early onset of AD.
Advertisement